US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.64

+0.11507.57%

Volume:500.66K

Turnover:809.26K

Market Cap:31.18M

PE:-3.52

High:1.68

Open:1.55

Low:1.55

Close:1.52

52wk High:2.56

52wk Low:0.7300

Shares:19.07M

Float Shares:14.81M

Volume Ratio:3.06

T/O Rate:3.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4640

EPS(LYR):-0.5085

ROE:-556.87%

ROA:-253.31%

PB:54.71

PE(LYR):-3.22

Loading ...

Overview Company News Filings

Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion

Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate

MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models

Mira Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview

Mira Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting

Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study

BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC Filing

Mira Pharmaceuticals Inc. Receives FDA Clearance for Ketamir-2 IND, Advancing U.S. Clinical Trials for Neuropathic Pain

Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction

Mira Pharmaceuticals Inc. Sells 1,550,741 Shares in Block Sale to Institutional Investor for $2 Million

Top Premarket Gainers

MT Newswires Live

24H｜Mira Pharma Soars 47%; Minim Surges 42%; Datadog Jumps 11%; AppLovin and Robinhood Drop 1%

Tiger Newspress

BUZZ-MIRA Pharmaceuticals jumps on positive preclinical data from marijuana-based pain relief drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.635,"timestamp":1757618013001,"preClose":1.52,"halted":0,"volume":500655,"delay":0,"floatShares":14806099,"shares":19069315,"eps":-0.464032,"marketStatus":"Trading","change":0.115,"latestTime":"09-11 15:16:54 EDT","open":1.55,"high":1.6796,"low":1.55,"amount":809263.147764,"amplitude":0.085263,"askPrice":1.64,"askSize":253,"bidPrice":1.63,"bidSize":492,"shortable":3,"etf":0,"ttmEps":-0.464032,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1757620800000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.55,"preClose":1.52,"latestTime":"09:29 EDT","volume":32356,"amount":52944.9575848,"timestamp":1757597344999},"postHourTrading":{"tag":"盘后","latestPrice":1.53,"preClose":1.52,"latestTime":"19:59 EDT","volume":4292,"amount":6545.1711,"timestamp":1757548793192},"volumeRatio":3.058013},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":14806099,"roa":"-253.31%","roe":"-556.87%","lyrEps":-0.508455,"volumeRatio":3.058013,"shares":19069315,"dividePrice":0,"high":1.6796,"amplitude":0.085263,"preClose":1.52,"low":1.55,"week52Low":0.73,"pbRate":"54.71","week52High":2.56,"institutionHeld":0,"latestPrice":1.635,"committee":0.320805,"eps":-0.464032,"divideRate":0,"volume":500655,"delay":0,"ttmEps":-0.464032,"open":1.55,"prevYearClose":1.14,"prevWeekClose":1.4,"prevMonthClose":1.37,"prevQuarterClose":1.21,"fiveDayClose":1.38,"twentyDayClose":1.49,"sixtyDayClose":1.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"MIRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1755576000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-09-10","current":-3.462659,"percent":0.209581,"low":-15.501022,"twenty":-3.506863,"median":-2.132112,"eighty":-1.474654,"high":-0.648567,"avg":-3.277723,"sd":3.247115,"marketCap":26887734},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-16","current":-3.015077,"twenty":-3.060231,"median":-1.929591,"eighty":-1.33782,"marketCap":23875388},{"date":"2025-05-23","current":-2.611651,"twenty":-3.060231,"median":-1.942197,"eighty":-1.340821,"marketCap":20680794},{"date":"2025-05-30","current":-2.845213,"twenty":-3.032803,"median":-1.954767,"eighty":-1.341164,"marketCap":22530296},{"date":"2025-06-06","current":-2.927246,"twenty":-3.016719,"median":-1.959543,"eighty":-1.343476,"marketCap":23179883},{"date":"2025-06-13","current":-2.649478,"twenty":-3.012039,"median":-1.970481,"eighty":-1.352726,"marketCap":20980332},{"date":"2025-06-20","current":-2.628111,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"marketCap":20811136},{"date":"2025-06-27","current":-2.585377,"twenty":-2.991346,"median":-2.003743,"eighty":-1.36142,"marketCap":20472743},{"date":"2025-07-03","current":-2.564011,"twenty":-2.980626,"median":-2.014046,"eighty":-1.36845,"marketCap":20303547},{"date":"2025-07-11","current":-2.564011,"twenty":-2.973678,"median":-2.023876,"eighty":-1.374721,"marketCap":20303547},{"date":"2025-07-18","current":-4.711669,"twenty":-3.002927,"median":-2.037346,"eighty":-1.385099,"marketCap":37310135},{"date":"2025-07-25","current":-4.058566,"twenty":-3.076478,"median":-2.047338,"eighty":-1.397154,"marketCap":32138433},{"date":"2025-08-01","current":-3.84864,"twenty":-3.389372,"median":-2.057134,"eighty":-1.420873,"marketCap":30476100},{"date":"2025-08-08","current":-3.195538,"twenty":-3.551253,"median":-2.064723,"eighty":-1.428551,"marketCap":25304398},{"date":"2025-08-15","current":-3.428789,"twenty":-3.546261,"median":-2.076725,"eighty":-1.436037,"marketCap":27151435},{"date":"2025-08-22","current":-3.438101,"twenty":-3.551253,"median":-2.088717,"eighty":-1.466225,"marketCap":26697041},{"date":"2025-08-29","current":-3.438101,"twenty":-3.546261,"median":-2.106877,"eighty":-1.473341,"marketCap":26697041},{"date":"2025-09-05","current":-3.388985,"twenty":-3.525507,"median":-2.115909,"eighty":-1.473341,"marketCap":26315654},{"date":"2025-09-10","current":-3.462659,"twenty":-3.506863,"median":-2.132112,"eighty":-1.474654,"marketCap":26887734}],"updateTime":1757611196689},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2560196237","title":"Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2560196237","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560196237?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:01","pubTimestamp":1755604907,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDLHjsBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2559100999","title":"Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559100999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559100999?lang=en_us&edition=fundamental","pubTime":"2025-08-16 00:14","pubTimestamp":1755274486,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryMira Pharmaceuticals Inc MIRA.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nL8N3U70YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2559962810","title":"Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559962810","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559962810?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:55","pubTimestamp":1755204924,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 18.18 percent increase over losses of $(0.11) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47141181/mira-pharmaceuticals-q2-eps-0-09-beats-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558664215","title":"MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2558664215","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558664215?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:02","pubTimestamp":1755000131,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLC7QCw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558983726","title":"Mira Pharmaceuticals Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558983726","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558983726?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:13","pubTimestamp":1754943186,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc  expected to post a loss of13cents a share - Earnings Preview Mira Pharmaceuticals Inc MIRA.OQ MIRA.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U31EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558577800","title":"Mira Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2558577800","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558577800?lang=en_us&edition=fundamental","pubTime":"2025-08-09 05:17","pubTimestamp":1754687820,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. is set to hold its annual meeting of stockholders on September 11, 2025. The meeting will be conducted exclusively online via a live audio-only webcast. During this important meeting, stockholder approvals will be sought for certain matters, including the proposed Merger.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL2dfcfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2555066783","title":"Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2555066783","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555066783?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:02","pubTimestamp":1753819362,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL5RJttj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2555670171","title":"BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555670171","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555670171?lang=en_us&edition=fundamental","pubTime":"2025-07-29 05:03","pubTimestamp":1753736633,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC FilingMira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - FDA CLEARS MIRA'S IND FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - PRECLINICAL DATA SHOWS ANALGESIC EFFECTS AND SAFETY - SEC FILINGMIRA PHARMACEUTICALS INC - KETAMIR-2 ACHIEVES GOOD BIOAVAILABILITY AND PENETRATION - SEC FILINGMIRA PHARMACEUTICALS INC - PLANS PHASE 2A TRIAL IN U.S. Q4 2025 - SEC FILINGSource text: [ID:n0001641172-25-021155]Further company coverage: MIRA.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP23L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2555709569","title":"Mira Pharmaceuticals Inc. Receives FDA Clearance for Ketamir-2 IND, Advancing U.S. Clinical Trials for Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709569","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555709569?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:02","pubTimestamp":1753732937,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Inc.  has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for Ketamir-2, a novel oral NMDA receptor antagonist aimed at treating neuropathic pain. This regulatory approval enables MIRA to initiate U.S.-based clinical trials. Ketamir-2 has demonstrated superior efficacy to existing treatments such as gabapentin and pregabalin in preclinical studies, with a favorable safety profile and no evidence of ketamine-associated neurotoxicity. MIRA is advancing through Phase 1 trials and plans to initiate U.S. Phase 2a trials by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL2psPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2550675725","title":"Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction","url":"https://stock-news.laohu8.com/highlight/detail?id=2550675725","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550675725?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:20","pubTimestamp":1752178808,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL3fq2NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2550575922","title":"Mira Pharmaceuticals Inc. Sells 1,550,741 Shares in Block Sale to Institutional Investor for $2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575922","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575922?lang=en_us&edition=fundamental","pubTime":"2025-07-09 05:26","pubTimestamp":1752009962,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. announced that on July 3, 2025, it sold a total of 1,550,741 shares of its common stock to an institutional investor at an average price of $1.2981 per share. The transaction, conducted through its at-the-market equity offering facility, generated approximately $2.0 million in gross proceeds. The transaction was facilitated by Rodman & Renshaw via the StockBlock platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLc2xNL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2548106801","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2548106801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548106801?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:05","pubTimestamp":1751544312,"startTime":"0","endTime":"0","summary":"FiEE  shares were up 37% in recent Thursday premarket activity, after the company said Wednesday it signed an asset purchase deal with Suzhou Yixuntong Network Technology to buy intellectual property and fixed assets for $1.4 million.Xponential Fitness  stock rose 21%, a day after the company said in a regulatory filing that the US Securities and Exchange Commission concluded its probe in the company \"without action.\"Mira Pharmaceuticals  shares climbed 18%, a day after the company said in a regulatory filing that preclinical results for its Mira-55 drug candidate demonstrated morphine-comparable pain relief in a validated animal model of inflammatory pain.Datadog  stock was 9% higher after S&P Dow Jones Indices said overnight that the company will join the S&P 500, effective July 9.Synopsys  shares were up 4.5% after the company said late Wednesday that the Bureau of Industry and Security of the US Department of Commerce notified it that export restrictions related to China have been ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2264538146.SGD","BK4543","LU0957791311.USD","LU1548497426.USD","BK4023","LU1720051017.SGD","LU1923622614.USD","BK4585","BK4533","BK4613","XPOF","LU1720051108.HKD","LU0390134368.USD","BK4535","LU2125909759.SGD","LU1803068979.SGD","LU0889565833.HKD","LU2458330169.SGD","LU1821325948.USD","DDOG","LU2063271972.USD","LU0096362180.USD","SGXZ23171101.USD","SNPS","LU2098885051.SGD","LU2360107168.USD","BK4528","LU0444971666.USD","LU2125909593.SGD","BK4551","MIRA","LU1951200564.SGD","LU0957808578.USD","LU1721428933.USD","LU0719512351.SGD","LU1861220033.SGD","LU1951198990.SGD","SG9999004303.SGD","LU1989764664.SGD","LU1878469433.USD","BK4539","LU1989764748.USD","LU1064131342.USD","MINM","LU2286300806.USD","LU0347712357.USD","FIEE","BK4007","LU1642822529.SGD","LU2433249047.HKD","LU1988902786.USD"],"gpt_icon":0},{"id":"1194188463","title":"24H｜Mira Pharma Soars 47%; Minim Surges 42%; Datadog Jumps 11%; AppLovin and Robinhood Drop 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194188463","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194188463?lang=en_us&edition=fundamental","pubTime":"2025-07-03 08:33","pubTimestamp":1751502830,"startTime":"0","endTime":"0","summary":"Shares of drug developer $Mira Pharma$ soared 46.8% in overnight trading. The company said its experimental drug, Mira-55, a non-psychoactive marijuana analog showed morphine-comparable pain relief in a preclinical animal trial.Shares of $Minim$ rallied 42.3% after the software provider acquired a portfolio of intellectual property and fixed assets from Suzhou Yixuntong Network Technology for $1.4 million.Software company $Datadog$ will be added to the S&P 500 index next week, replacing Juniper ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIEE","APP","HOOD","DDOG","MINM","MIRA"],"gpt_icon":1},{"id":"2548074810","title":"BUZZ-MIRA Pharmaceuticals jumps on positive preclinical data from marijuana-based pain relief drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2548074810","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548074810?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:52","pubTimestamp":1751489558,"startTime":"0","endTime":"0","summary":"BUZZ-MIRA Pharmaceuticals jumps on positive preclinical data from marijuana-based pain relief drug** Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 45.9% to $1.81 in extended trading  ** Company says its experimental drug, Mira-55, a non-psychoactive marijuana analog showed morphine-comparable pain relief in a preclinical animal trial ** Mira-55 is a synthetic analog of marijuana designed to target CB2 receptors, which are associated with anti-inflammatory effects - MIRA      ** In the trial the drug significantly reduced pain sensitivity and showed efficacy comparable to morphine, the opioid control - company** Company says it previously received confirmation from the U.S. Drug Enforcement Administration that Mira-55 is not classified as a controlled substance, removing a key regulatory barrier to clinical development ** Company adds it continues to advance Mira-55 towards human trials** Up to last close, stock up 8.8% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL4N3SZ1EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}